Citius Oncology (CTOR) Q1 2025 earnings summary

Executive summary

• Achieved first reported revenue of $3.9 million following the U.S. commercial launch of LYMPHIR in December 2025.

• Transitioned from a development-stage to a commercial-stage oncology company with an FDA-approved therapy for relapsed or refractory Stage I-III CTCL.

• Completed a merger and recapitalization in August 2024, resulting in Citius Pharma owning 92.3% of outstanding shares.

• Focused on accelerating physician adoption, expanding patient access, and supporting a concentrated prescriber base using an AI-enabled commercial platform.

• Operations were funded by Citius Pharma prior to commercial launch, with ongoing efforts to raise additional capital and generate revenue from LYMPHIR sales.

Financial highlights

• Revenue for the quarter ended December 31, 2025, was $3.9 million, reflecting initial LYMPHIR sales.

• Net loss for the quarter ended December 31, 2025 was $5.5 million, or $(0.06) per share, compared to $6.7 million, or $(0.09) per share, in the prior-year period.

• Cash and cash equivalents totaled $7.3 million as of December 31, 2025, compared to $112 at December 31, 2024.

• Completed a registered offering in December 2025, generating net proceeds of $15.1 million.

• Operating expenses decreased to $3.9 million from $6.4 million year-over-year, with R&D and G&A expenses both declining.

Outlook and guidance

• Management is focused on execution, capital management, and evaluating strategic opportunities to enhance long-term shareholder value.

• Plans to expand field presence and international access through regional partners and Named Patient Programs in Europe and the Middle East.

• Ongoing investigator-initiated Phase I studies for potential label expansion, including combinations with pembrolizumab and as part of lymphodepletion regimens before CAR-T therapy.

• Funding from Citius Pharma was expected to support operations through March 2025; additional capital will be needed beyond that period.